$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins

FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- The damage done by the opioid epidemic has caused families grief and loss, but recent developments in the case against Purdue Pharma will see some restitution for the family. A potential $10 billion will be going toward fighting the opioid crisis that killed upward of 500,000 Americans in the past two decades. The Sackler family that owns Purdue Pharma will forfeit ownership of Purdue Pharma and pay $4.5 billion for the damage done by opioids like its best-selling Oxycontin. Fortunately, a new flock of companies is upending the traditional view of medicine by providing psychedelic treatments into their research and opening clinics to treat patients. Companies like Revitalist Lifestyle and Wellness Ltd. (CSE:CALM), Atai Life Sciences N.V. (NASDAQ:ATAI), Cybin (NYSE:CYBN), Seelos Therapeutics, Inc. (NASDAQ:SEEL) and Tonix Pharmaceuticals (NASDAQ:TNXP) are researching, developing, and bringing to market new treatments in order to avoid the mistakes of the past.

Revitalist Lifestyle and Wellness Ltd. (CSE:CALM) has just announced it has opened its fifth clinic in Raleigh, North Carolina. The city of Raleigh was chosen for its leading scholarly institutions and healthcare industry. With 14 treatment rooms, the clinic will have the ability to treat over 14,500 patients annually. The clinic will participate in advocacy programs working with Veterans Affairs and assisting veterans struggling with Post Traumatic Stress Disorder, Pain Syndromes, Major Depressive Disorder, and Suicidal Ideations gain greater access to care and is expected to generate approximately $7.1 million in revenue at full capacity.

Revitalist will aim to bring its unique blend of comprehensive care and future-centric treatments provided by medical professionals, mental health experts, and chronic pain specialists. As the state ranks 21st in the country for the prevalence of mental illness, Revitalist's clinic is well-placed to serve the people of Raleigh and the surrounding communities in a more holistic and natural way.

Revitalist now has a total of five clinics since opening the first in 2018. The company operates across the United States and will continue the expansion across the US is advancing its mission of bringing new, comprehensive care solutions to patients in both mental health care and pain management.   If you'd like to learn more about Revitalist Lifestyle and Wellness Ltd. (CSE:CALM), click here.

Companies Taking a New Approach to Treatment and Avoiding the MIstakes of the Past

Seelos Therapeutics, Inc. (NASDAQ:SEEL) is a clinical-stage biopharmaceutical company developing therapies for many central nervous system disorders and rare diseases. It is also advancing its mission and announced on January 27 that it had been selected as one of the 17 companies to be included in the world's first psychedelic Exchange Traded Fund (ETF). The fund has begun trading on the NEO exchange under the symbol PSYK. This opens the avenues for investors to gain exposure to the growing psychedelic market.

Cybin (NYSE:CYBN) is the first for the sector to list on the NYSE, and is a validation for both the company and the industry. Cybin is currently developing a pipeline of psychedelic molecules for treating mental health conditions, including a proprietary formulation of psilocybin. This formulation is currently in phase 2 clinical trials.

Atai Life Sciences (NASDAQ:ATAI) has a revolutionary digital therapeutic platform called Itrospect Digital Therapeutics. The company has announced it will begin a usability study of the app for support of standard of care ketamine therapy for patients with treatment-resistant depression. With digital health services growing in popularity and need, Atai is hoping to bring its app to more users to help treat mental illness in a more productive way without the need for addictive medications.

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ:TNXP) has a large pipeline of innovative and proprietary therapeutics to address the needs of patients. The company also takes an approach that focuses on less addictive treatment. The company's portfolio includes small molecules and biologics to treat pain, neurologic, and psychiatric disorders, along with addiction disorders. The company will be a presenter at the H.C. Wainwright Global Investment Conference from September 13-15, and aims to bring investors awareness to the company through the conference.

Companies are taking a good, long look at the damage done by companies like Purdue Pharma, and developing new treatments using psychedelics to provide better care for patients. Revitalist Lifestyle and Wellness Ltd. continues to move toward that goal by opening more clinics and bringing its services to more people across the country.

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
 
 The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Revitalist Lifestyle and Wellness Ltd.
 
 FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
 
 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
 
 Media Contact:
 FN Media Group, LLC
 info@financialnews.com
 +1(561)325-8757

SOURCE Microsmallcap.com